Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Other ETFs median (248 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 09 Nov 2020 – 20 Aug 2026, limited by Axis NIFTY Bank ETF. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Axis NIFTY Bank ETF | Nifty Bank |
|---|---|---|
| 09 Nov 2020 | ₹100.00 | ₹100.00 |
| 04 May 2021 | ₹117.46 | ₹117.20 |
| 27 Oct 2021 | ₹149.22 | ₹148.45 |
| 21 Apr 2022 | ₹134.28 | ₹133.71 |
| 13 Oct 2022 | ₹141.76 | ₹140.28 |
| 07 Apr 2023 | ₹150.57 | ₹149.06 |
| 30 Sep 2023 | ₹164.78 | ₹161.92 |
| 24 Mar 2024 | ₹173.05 | ₹170.20 |
| 16 Sep 2024 | ₹194.03 | ₹189.41 |
| 11 Mar 2025 | ₹177.94 | ₹173.80 |
| 02 Sep 2025 | ₹200.96 | ₹194.89 |
| 25 Feb 2026 | ₹228.31 | ₹221.70 |
| 20 Aug 2026 | ₹216.10 | ₹208.82 |
| Metric | Axis NAV ₹593.71 Very High risk ★★★☆☆ | Category median Other ETFs · 248 funds |
|---|---|---|
| +3.62% | +3.65% | |
| +10.04% | +10.51% | |
| +11.05% | +9.28% | |
| — | +11.93% | |
| +14.27% | +10.38% | |
| +9.79% | — | |
| +12.94% | +14.30% | |
| +12.42% | +13.74% | |
| — | +12.83% | |
| Risk | ||
| 15.99% | 15.45% | |
| 0.22 | 0.28 | |
| 0.31 | 0.41 | |
| -20.59% | -20.59% | |
| Nifty Bank | — | |
| +0.56% | +0.80% | |
| 1.00 | 1.00 | |
| 100.7% | 102.1% | |
| 97.7% | 96.4% | |
| 0.25% | 0.32% | |
| ₹342.94Cr | ₹137.31Cr | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| Karthik Kumar | — | |
| 09 Nov 2020 | — | |
| 14 | — | |
| 86.8% | — | |
| — | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.